Company Filing History:
2 out of 216 
2 out of 138 
1 out of 179 
Years Active: 2012-2016
Title: **Janine L Ferrant-Orgettas: Innovator in Binding Protein Technology**
Introduction
Janine L Ferrant-Orgettas is a prominent inventor based in Gloucester, MA, known for her significant contributions in the field of binding proteins, particularly those that target CD154. Her innovative work has resulted in the issuance of three patents, showcasing her influence and expertise in biopharmaceutical advancements.
Latest Patents
Among her latest patents, Ferrant-Orgettas has developed binding proteins, including antibodies, antibody derivatives, and antibody fragments that specifically bind the CD154 (CD40L) protein. This breakthrough invention not only includes a chimeric, humanized, or fully human antibody but also specifies a unique epitope binding involving a humanized Fab fragment. Notably, the CD154 binding proteins created by her possess reduced effector functions compared to second anti-CD154 antibodies. This innovation has promising applications in diagnostic and therapeutic methods for treating diseases related to undesirable immune responses mediated by CD154-CD40 interactions.
Career Highlights
Over the years, Janine has worked with esteemed organizations, including Biogen Idec MA Inc. and UCB Biopharma. Her experiences at these companies have profoundly influenced her research and inventions, further solidifying her reputation in the biopharmaceutical industry.
Collaborations
In her journey as an innovator, Janine has collaborated with notable figures in the field, such as Linda C Burkly and Ellen A Garber. These professional relationships have fostered an environment of shared knowledge and innovation, enabling her to enhance her contributions to the scientific community.
Conclusion
Janine L Ferrant-Orgettas stands out as a significant figure in the realm of binding proteins, utilizing her expertise to develop innovative solutions for complex medical challenges. Her work continues to pave the way for advancements in the treatment and prevention of diseases, making her a valuable asset to the field of biotechnology.